Athersys Inc

Committed to developing therapies to extend and enhance the quality of human life after stroke and other hard to treat diseases.

[Athersys Inc @athersys]

Athersys Reports Third Quarter 2023 Financial Results and Business Highlights

https://t.co/hYphfJnttV

[Athersys Inc @athersys]

Athersys Extends Near Term Liquidity with Proceeds from Warrant Inducement and Global ARDS License with Healios to Explore Strategic Alternatives

https://t.co/rYpgNWdJLf

[Athersys Inc @athersys]

Athersys Reports Interim Analysis Results of MASTERS-2 Clinical Study with MultiStem in Ischemic Stroke, Signs Memorandum of Understanding (MOU) for Global ARDS License with Healios

https://t.co/BgwG0K0n7N

[Athersys Inc @athersys]

We're excited for @alliancerm’s #CGMesa23 next week! Looking forward to connecting with senior executives and key stakeholders in the cell and gene therapy industry.

Learn more: https://t.co/nELS8Y1qcO

[Athersys Inc @athersys]

Athersys Licenses its Animal Health Assets to Ardent Animal Health

https://t.co/Ubi78u9lIT

[Athersys Inc @athersys]

We are excited to announce that Jane Wasman, JD, has been appointed Athersys Board Chair. Read more here: https://t.co/FqHhd4CA3e

[American Heart Association @American_Heart]

Van had a stroke early on a Monday morning. His wife, Angela, knew the signs and acted fast. Thanks to her, he got clot-busting medication within an hour. He was home by Saturday with no physical or cognitive impairments. Read his Story from the Heart: https://t.co/M7Vp0tMwpR

[Athersys Inc @athersys]

We hosted our 2023 Annual Meeting of Stockholders yesterday. In case you missed it, you can listen to a replay here - https://t.co/BQHVLxkyER

[Athersys Inc @athersys]

Our Annual Meeting will begin at 8:30 a.m. ET this morning. Stockholders and guests can join beginning now here: https://t.co/gh6eh3f0Rf

[Athersys Inc @athersys]

Tomorrow is our Annual Meeting of Stockholders. The meeting will begin at 8:30 a.m. ET. If you're a stockholder, please have your control number ready. Both stockholders and guests can join 15 minutes prior to the start of the meeting here: https://t.co/gh6eh3f0Rf

[Athersys Inc @athersys]

The American Stroke Association has a number of great resources for stroke patients and caregivers, including a directory of local support groups. Find the support group nearest to you here: https://t.co/wh8Upww2RA

[Athersys Inc @athersys]

Reminder: Our Annual Meeting of the Stockholders is next Wednesday, 9/27 at 8:30 AM ET. The meeting will be open to both stockholders and guests. If you are a stockholder and wish to vote during the meeting, you will need to join with your control number.

https://t.co/ccujikAULs

[WorldStrokeCampaign @WStrokeCampaign]

High blood pressure causes no symptoms and nearly half of all people living with the deadly condition don’t know they have it. A new report by @WHO in partnership with @ResolveTSL sheds light on the cause of half of all strokes - and the race to stop it. https://t.co/tlcmWkAMPt

[Athersys Inc @athersys]

Following major injuries or systemic infections, the immune system may react in a harmful manner. Factors expressed by MultiStem cells have the potential to deliver therapeutic benefit in several ways, such as reducing acute inflammation while also promoting tissue repair.

#ATHXfacts

[Heart & Stroke @HeartandStroke]

More people are surviving stroke because of increased public awareness, better treatment and coordinated systems of care. But four in 10 Canadians do not know any of the FAST signs of stroke. Help us share this life-saving message.
Learn more: https://t.co/94Dejn4MLZ.

[Athersys Inc @athersys]

We were excited to share the news about @UniofNewcastle's kidney study grant last week, as preclinical research has shown MultiStem may be beneficial in organ transplants.

This research is also highly relevant to our Phase 2 clinical trial in trauma which assesses acute kidney injury as the primary outcome.

View our full clinical pipeline below.

https://t.co/JAdx4BDOpb

[Athersys Inc @athersys]

Reminder: The interim analysis of the MASTERS-2 trial will determine whether the current proposed study size is still sufficiently powered to achieve statistical significance following the change in primary endpoint. We expect these results to be available in October.

#MultiStem #celltherapy #clinicaltrials

[Athersys Inc @athersys]

Today we remember and honor all those affected by the events of 9/11.

[Athersys Inc @athersys]

We wish Sarah a great day at Massachusetts General Hospital as she speaks to their Department of Neurology on MultiStem Cell Therapy for the Treatment of Acute Neurological Indications!

#MultiStem #CellTherapy #Neurology

[Stroke Association @TheStrokeAssoc]

Steve, Tom and Julie were left with aphasia after their strokes.

When the Words Away Went, follows their journeys as they prepare for some of the most challenging milestones in their recovery so far.

Watch the film online now at https://t.co/gFgDdCOJwJ or stream on Channel 4.